MA44851A - Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations - Google Patents

Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations

Info

Publication number
MA44851A
MA44851A MA044851A MA44851A MA44851A MA 44851 A MA44851 A MA 44851A MA 044851 A MA044851 A MA 044851A MA 44851 A MA44851 A MA 44851A MA 44851 A MA44851 A MA 44851A
Authority
MA
Morocco
Prior art keywords
pyridinyltriazole
derivatives substituted
compounds
amid groups
amid
Prior art date
Application number
MA044851A
Other languages
English (en)
Other versions
MA44851B1 (fr
Inventor
Anja Buchmüller
Hana Cernecka
Marie-Pierre Collin
Karoline DRÖBNER
Chantal Fürstner
Peter Kolkhof
Axel Kretschmer
Klemens Lustig
Thomas Mondritzki
Thomas Neubauer
Elisabeth Pook
Heiko Schirmer
Carsten Schmeck
Hanna Tinel
Pierre Wasnaire
Matthias Beat Wittwer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA44851A publication Critical patent/MA44851A/fr
Publication of MA44851B1 publication Critical patent/MA44851B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de 5-(carboxamide)-1-pyridinyl-1,2,4-triazole, des procédés de préparation de ces composés, des compositions pharmaceutiques contenant ces composés, et l'utilisation de ces composés ou de ces compositions pour le traitement et/ou la prévention de maladies, en particulier pour le traitement et/ou la prévention de maladies cardiovasculaires et rénales.
MA44851A 2016-05-03 2017-05-02 Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations MA44851B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16168165 2016-05-03
PCT/EP2017/060356 WO2017191102A1 (fr) 2016-05-03 2017-05-02 Dérivés de pyridinyltriazole à substitution amide et leurs utilisations

Publications (2)

Publication Number Publication Date
MA44851A true MA44851A (fr) 2019-03-13
MA44851B1 MA44851B1 (fr) 2021-09-30

Family

ID=55910850

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44851A MA44851B1 (fr) 2016-05-03 2017-05-02 Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations

Country Status (42)

Country Link
US (4) US9988367B2 (fr)
EP (1) EP3452463B1 (fr)
JP (1) JP6932140B2 (fr)
KR (1) KR20190003655A (fr)
CN (2) CN109415347B (fr)
AR (1) AR108262A1 (fr)
AU (1) AU2017259870B2 (fr)
BR (1) BR112018072542A2 (fr)
CA (1) CA3022749A1 (fr)
CL (1) CL2018003105A1 (fr)
CO (1) CO2018011933A2 (fr)
CR (1) CR20180522A (fr)
CU (1) CU24567B1 (fr)
CY (1) CY1124084T1 (fr)
DK (1) DK3452463T3 (fr)
DO (1) DOP2018000240A (fr)
EA (1) EA035596B1 (fr)
EC (1) ECSP18081881A (fr)
ES (1) ES2866109T3 (fr)
GE (2) GEP20207158B (fr)
HR (1) HRP20210648T1 (fr)
HU (1) HUE053908T2 (fr)
IL (1) IL262557B (fr)
JO (1) JOP20170105B1 (fr)
LT (1) LT3452463T (fr)
MA (1) MA44851B1 (fr)
MX (1) MX381787B (fr)
NI (1) NI201800115A (fr)
PE (1) PE20190116A1 (fr)
PH (1) PH12018502268A1 (fr)
PL (1) PL3452463T3 (fr)
PT (1) PT3452463T (fr)
RS (1) RS61771B1 (fr)
SG (1) SG11201809752VA (fr)
SI (1) SI3452463T1 (fr)
SV (1) SV2018005771A (fr)
TN (1) TN2018000368A1 (fr)
TW (1) TWI772295B (fr)
UA (1) UA123791C2 (fr)
UY (1) UY37220A (fr)
WO (1) WO2017191102A1 (fr)
ZA (1) ZA201808131B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3458443B1 (fr) 2016-05-03 2020-08-19 Bayer Pharma Aktiengesellschaft Dérivés sulfonamides aromatiques
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
CN109071464A (zh) * 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基三唑衍生物及其用途
KR20190003536A (ko) * 2016-05-03 2019-01-09 바이엘 파마 악티엔게젤샤프트 5-히드록시알킬-치환된 1-페닐-1,2,4-트리아졸 유도체의 제조 방법
US10893352B2 (en) * 2016-08-24 2021-01-12 Matthew Hawkes Programmable interactive stereo headphones with tap functionality and network connectivity
WO2018163204A1 (fr) * 2017-03-08 2018-09-13 Yogee's Bioinnovations Private Limited Inhibiteurs de la cathepsine d et de l'angiogenèse et leurs compositions de ceux-ci destinées au traitement du cancer du sein
EP3665705B1 (fr) 2017-08-08 2024-12-18 Fresenius Medical Care Holdings, Inc. Systèmes et procédés de traitement et d'estimation de la progression d'une maladie rénale chronique
WO2019081306A1 (fr) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Dérivés de triazole substitués et utilisations associées
EP3700896A1 (fr) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Dérivés de triazole substitués par une amine et utilisations associées
CA3084308A1 (fr) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Derives de triazole substitues et utilisations associees
EP3700897A1 (fr) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Dérivés de triazole substitués et utilisations associées
KR20200069361A (ko) * 2017-10-24 2020-06-16 바이엘 악티엔게젤샤프트 치환된 트리아졸 유도체의 전구약물 및 그의 용도
WO2019081303A1 (fr) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Dérivés de triazole substitués et utilisations associées
WO2019081291A1 (fr) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ci
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
US11020351B2 (en) * 2018-03-26 2021-06-01 Hetero Labs Limited Stable bilayer tablet compositions
WO2019199273A1 (fr) * 2018-04-10 2019-10-17 Hewlett-Packard Development Company, L.P. Matériaux de construction teints préchauffés à sources de préchauffage
KR20260018202A (ko) * 2019-12-24 2026-02-06 도쿄엘렉트론가부시키가이샤 성막 방법 및 성막 시스템
WO2021252951A1 (fr) 2020-06-12 2021-12-16 Vanderbilt University Méthodes de traitement de troubles de motilité gastro-intestinale
WO2021259852A1 (fr) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Procédé de préparation de dérivés de 5-(alcoxycarbonyle)-et de 5- (carboxamide)-1-aryl-1,2,4-triazole
WO2022112213A1 (fr) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Formes cristallines de 3-[[3-(4-chlorophényl)-5-oxo-4-((2s)-3,3,3-trifluoro-2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]méthyl]-1-[3- (trifluorométhyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
WO2024118667A1 (fr) * 2022-11-29 2024-06-06 The United States Government As Represented By The Department Of Veterans Affairs Inhibiteurs eif4a1 à activité antitumorale
WO2026035773A1 (fr) * 2024-08-06 2026-02-12 Retex Pharmaceuticals, Inc. Modulateurs du récepteur 2 de la vasopressine et leurs procédés d'utilisation

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0586513A1 (fr) 1991-05-10 1994-03-16 Merck & Co. Inc. Derives acides d'aralkyltriazole actifs en tant qu'antagonistes de l'angiotensine ii
WO1993017681A1 (fr) 1992-03-02 1993-09-16 Abbott Laboratories Antagonistes du recepteur d'angiotensine ii
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
HUP0100178A3 (en) 1997-12-17 2002-12-28 Merck & Co Inc Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
BR9912392A (pt) 1998-07-24 2001-05-08 Bayer Ag Benzoilcicloexanodionas substituìdas
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
KR20020005653A (ko) 1999-04-01 2002-01-17 실버스타인 아써 에이. 소르비톨 디하이드로게나제 저해제로서의 아미노피리미딘
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (fr) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. Derives de 4h-1,2,4-triazole-3(2h)-thione tenant lieu d'inhibiteurs de sphingomyelinase
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CA2518852A1 (fr) 2003-03-14 2004-09-30 Merck & Co., Inc. Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique
EP1689252A2 (fr) 2003-06-27 2006-08-16 Berglin Corporation of Washington Machine permettant de noyauter et trancher avec precision et avec une faible contrainte les pommes et autres fruits a coeur tendre ou a noyau
BRPI0417267A (pt) * 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
CN1933832A (zh) 2004-03-08 2007-03-21 惠氏公司 离子通道调节剂
EP1723117A4 (fr) 2004-03-08 2009-12-02 Wyeth Corp Modulateurs de canal ionique
CA2563963A1 (fr) 2004-04-28 2005-11-10 Pfizer Inc. Derives 3-heterocyclyl-4-phenyl-triazole comme inhibiteurs de la vasopressine par recepteur
WO2006066133A2 (fr) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Inhibiteurs d'histone desacetylase
WO2006117657A1 (fr) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Derives de triazolone utilises comme agents anti-inflammatoires
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AU2011219746B2 (en) 2010-02-27 2015-04-23 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PH12013500055A1 (en) 2010-07-09 2017-08-23 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
EP2623499B1 (fr) * 2010-10-01 2015-04-22 Taisho Pharmaceutical Co., Ltd Dérivé de 1,2,4-triazolone
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (fr) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Inhibiteurs de cystéine protéases, les cathepsines
EP2828257B1 (fr) 2012-03-22 2017-07-26 Biota Europe Ltd Composés antibactériens
EA032137B1 (ru) 2014-11-03 2019-04-30 Байер Фарма Акциенгезельшафт Производные гидроксиалкил-замещенного фенилтриазола и их применение
KR20190003536A (ko) * 2016-05-03 2019-01-09 바이엘 파마 악티엔게젤샤프트 5-히드록시알킬-치환된 1-페닐-1,2,4-트리아졸 유도체의 제조 방법
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
CN109071464A (zh) * 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基三唑衍生物及其用途

Also Published As

Publication number Publication date
SV2018005771A (es) 2019-01-04
SG11201809752VA (en) 2018-12-28
UY37220A (es) 2017-11-30
PT3452463T (pt) 2021-04-28
JP2019514945A (ja) 2019-06-06
US10472348B2 (en) 2019-11-12
NI201800115A (es) 2019-03-14
CR20180522A (es) 2019-01-15
AU2017259870B2 (en) 2021-07-15
GEP20207158B (en) 2020-10-12
MX2018013335A (es) 2019-05-09
TN2018000368A1 (en) 2020-06-15
US9988367B2 (en) 2018-06-05
WO2017191102A1 (fr) 2017-11-09
ZA201808131B (en) 2021-05-26
MA44851B1 (fr) 2021-09-30
CO2018011933A2 (es) 2018-11-22
ES2866109T3 (es) 2021-10-19
CN113121504A (zh) 2021-07-16
AR108262A1 (es) 2018-08-01
PE20190116A1 (es) 2019-01-16
HUE053908T2 (hu) 2021-07-28
HRP20210648T1 (hr) 2021-05-28
US20190144423A1 (en) 2019-05-16
LT3452463T (lt) 2021-04-26
DK3452463T3 (da) 2021-04-26
ECSP18081881A (es) 2018-11-30
CN109415347B (zh) 2021-05-07
DOP2018000240A (es) 2019-03-15
JP6932140B2 (ja) 2021-09-08
EP3452463A1 (fr) 2019-03-13
TWI772295B (zh) 2022-08-01
PL3452463T3 (pl) 2021-08-09
CA3022749A1 (fr) 2017-11-09
BR112018072542A2 (pt) 2019-03-26
KR20190003655A (ko) 2019-01-09
EA035596B1 (ru) 2020-07-14
IL262557A (en) 2018-12-31
UA123791C2 (uk) 2021-06-02
JOP20170105B1 (ar) 2022-03-14
CU24567B1 (es) 2022-01-13
CU20180134A7 (es) 2019-06-04
EP3452463B1 (fr) 2021-03-24
RS61771B1 (sr) 2021-05-31
SI3452463T1 (sl) 2021-07-30
US20200017473A1 (en) 2020-01-16
EA201892505A1 (ru) 2019-04-30
AU2017259870A1 (en) 2018-11-15
MX381787B (es) 2025-03-13
IL262557B (en) 2022-01-01
GEAP202014945A (en) 2020-05-11
TW201806941A (zh) 2018-03-01
US20180251447A1 (en) 2018-09-06
CN109415347A (zh) 2019-03-01
CY1124084T1 (el) 2022-05-27
CL2018003105A1 (es) 2019-02-15
US11091463B2 (en) 2021-08-17
US20170320854A1 (en) 2017-11-09
PH12018502268A1 (en) 2019-07-15

Similar Documents

Publication Publication Date Title
MA44851A (fr) Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA50240B1 (fr) Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation
MA42376B1 (fr) Dérivés d'oxopyridine substitués
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA44474B1 (fr) Inhibiteurs de la ferroportine
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA35576B1 (fr) Nouveaux composés
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA44965A (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
FR3078704B1 (fr) Derives d'isohexide et leurs utilisations
FR3026105B1 (fr) Composition contenant au moins un inhibiteur de certaines chimiokines, son procede d'obtention et son utilisation dermocosmetique ou pharmaceutique
MA49994B1 (fr) Composés macrocycliques pour le traitement de maladie
FR3124946B1 (fr) Nouveaux composés dérivés des schweinfurthines G, E, F
MA53413A1 (fr) Composés antibiotiques, leurs procédés de fabrication, compositions pharmaceutiques les contenant et leurs utilisations